EOFLOW is starting 2017 on a high note: the company successfully closed its Series-B round of funding.  Three major venture capital firms invested some $5.5M in this round, including two large firms each managing over $1B funds.  With the latest round of funding, combined with the company's current cash reserve and government grants, EOFLOW is well positioned for its first commercial product launch scheduled for later this year, as well as for execution of follow-on product development plans. 

EOFLOW will present at the upcoming RESI Innovation Challenge to be held in San Francisco on January 10, 2017.  There were more than 100 applicants to the event, and we're proud to be chosen as one of the 30 finalists.  Check us out at: http://www.resiconference.com/innovation-challenge/   

EOFLOW today unveiled the final design of its first smart wearable insulin pump, EOPatch.  The new design is much slimmer than the previously publicized design, with a dimension of 49mm x 32mm x 12.6mm.  With the new footprint, EOPatch is the smallest known wearable insulin pump with adjustable basal and bolus delivery.  The new design can be found on our website: www.eoflow.com 

After many years of development and refinements, EOFLOW's smart, disposable wearable insulin pump, EOPatch, has been officially submtted for verification and validation tests on 9/5/2016.  We expect to be able to market the product in the global market in 2017.

EOFLOW's smart disposable wearable insulin pump, EOPatch, has been chosen by the Korean government as one of the twenty devices chosen this year as a part of 'Next Generation Medical Device 100' which are meant to represent the most promising 100 new medical devices for the country.  The selected companies will be supported by a group of experts and mentors to help expedite the regulatory approvals.  This will ensure a more prompt debut of our product in 2017!

EOFLOW exhibits its commercial EOPatch wearable disposable insulin delivery product at the 52st EASD (European Association for the Study of Diabetes) Annual Meeting held in Munich, Germany, 9/12-16.  EOFLOW's booth is Q.02. 

EOFLOW exhibits the latest working sample of EOPatch wearable disposable insulin delivery product at a business partner’s booth at the 76th Scientific Sessions of ADA (American Diabetes Association) held in New Orleans, LA, 06/10-14. 

Aju News, a major economics newspaper in Korea, runs an article on EOFLOW and its EOPatch wearable disposable insulin pump. To read the Korean article, click the link below: ​http://www.ajunews.com/view/20160615013058993 

EOFLOW has exhibited its EOPatch wearable disposable insulin pump products at the 2016 Korea International Medical & Hospital Equipment Show (KIMES).  Many potential business partners and end users visited our booth, with a significant number of Type-1 diabetic patients adding their names to the growing list of clinical trial volunteers.    

Eoflow has moved to a new location in Healthcare Innovation Park (HIP) run by Seoul National University Bundang Hospital (SNUH), located in Bundang, Korea.  The new building is located in a 45,000m^2 campus situated at the foot of a green hill and boasts more than 78,000m^2 of office space.  HIP promises to be a major healthcare innovation hub in Korea that nurtures synergistic business opportunities by facilitating cooperation among medical facilities, universities and healthcare companies large and small.  HIP is not just a phy...